Loading...

Longeveron Inc.

LGVNNASDAQ
Healthcare
Biotechnology
$0.68
$-0.01(-2.13%)

Longeveron Inc. (LGVN) Company Profile & Overview

Explore Longeveron Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Longeveron Inc. (LGVN) Company Profile & Overview

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

SectorHealthcare
IndustryBiotechnology
CEOMohamed Wa'el Ahmed Hashad

Contact Information

305 909 0840
1951 NW 7th Avenue, Miami, FL, 33136

Company Facts

25 Employees
IPO DateFeb 12, 2021
CountryUS
Actively Trading

Frequently Asked Questions

;